Although the development of the ASK1 inhibitor GS4997 has progressed to phase III clinical trials, two of its key clinical trials for the treatment of NASH have failed, casting reservations on the development of drugs for this disease target. This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.